Nex Playground Announces Summer of Fun Game Lineup Featuring New Games With Zumba and Sesame Workshop

Six new motion games continue Nex's mission to provide healthy, affordable, and accessible play solutions for kids to move more and bond with friends and family
SAN FRANCISCO, June 04, 2025--(BUSINESS WIRE)--Nex, the leading motion technology and entertainment company, today announced its Summer 2025 game lineup for Nex Playground, the active play system that gets families moving together. Headlining the slate are two standout partnerships: a delicious and playful puzzle adventure starring Sesame Street's Cookie Monster and a high-energy fitness experience created in collaboration with Zumba®. Together with four additional titles spanning sports, fantasy, and trivia, the lineup builds on Nex Playground's growing catalog of motion games that promote healthy, joyful, and communal active play for everyone in the family.
With school out and warmer weather coming, kids and families will enjoy having a variety of indoor activities they can play all summer long. Nex Playground is keeping kids moving this summer with a fresh lineup of games:
Sesame Street's Cookie Monster's Cookie Factory – Join Cookie Monster in a fun-filled puzzle adventure. Players take on cookie-themed challenges focused on sorting, pattern recognition, and hand-eye coordination. Team up and work together to solve sweet puzzles and help Cookie Monster keep the nummie, nummie treats under control!
Zumba – A first-of-its-kind Zumba® experience that combines immersive motion tracking with gamified scoring and progression. Unlock new songs, styles, and dance moves while progressing through increasingly challenging routines. Developed in collaboration with Zumba's globally renowned brand, this innovative title brings the energy and excitement of the studio straight to your living room.
Brainy Inc. – Step into the fast-paced world of a factory floor, where you play as a robot in the final stages of assembly. Before earning your place outside the factory, you'll face a series of challenging tests packed with brain teasers and tricky questions. Outsmart the competition, rack up points, and prove your brilliance to claim the title of the smartest robot at Brainy Inc!
Mingle – A vibrant matching game from Cookiecrayon, the creators of Nex Playground's Aeon Guard. Featuring quirky characters and a relaxing pace, the game brings a laid-back charm to the summer lineup.
Homerun Heroes: Starstrikers – A third-person baseball batting game. Players swing to strike home runs, smash targets, and unlock a variety of costumes and bats to win the ultimate title of Starstrikers. This game features both 1v1 and 2v2 player modes, so no one's sitting on the bench.
Sword Slash Adventure – A storybook-inspired action game where players dive into a whimsical, magical world, battling a variety of monsters to unlock new worlds and engage in boss battles. An evolution of Nex Labs' original Sword Slash title, this expanded adventure includes new boss battles and equipment upgrades.
"We're looking forward to expanding Nex Playground's game library with this summer's diverse and creative lineup," said David Lee, CEO and Co-Founder of Nex. "From educational puzzles and trivia challenges to sports titles and our first-ever Zumba experience, Nex Playground has the ideal lineup to help keep kids and families stay active throughout the summer. We're committed to building games that resonate with our community, and will continue to build our platform to focus on entertainment that is accessible to the whole family."
Nex Playground is a controller-free console designed for families with young kids, making active, communal play more accessible and engaging than ever. Fully motion-powered gameplay means body movements are used rather than controllers, getting players to get off the couch and making physical activity fun for all ages. Additionally, Nex Playground is kidSAFE+ COPPA certified, with no internet connectivity, online interactions, ads, and in-game purchases, making it a standout family gaming option. All data stays local to the device, and the system comes with a built-in camera cover, highlighting Nex's commitment to privacy and safety. After a strong first year at retail in 2024 selling over 200,000 units to date, Nex Playground is gaining serious traction as a top choice for family gaming.
Families interested in purchasing Nex Playground can find the console on Amazon as well as in Best Buy®, Target® and Walmart® online and select retail stores nationwide. Store availability can be found at https://nexplayground.com/stores.
The new summer games will be progressively released on Nex Playground starting this July and will be included in the Play Pass content subscription bundle for families, which is sold separately and can easily be added anytime. To learn more about Nex Playground, visit https://nexplayground.com.
About NexNex is helping families reconnect with the joy of movement through fun, social, and interactive content that's accessible to all ages. Its award-winning Nex Playground active play system launched in December 2023, is designed in California, manufactured by Skyworth, a leader in home entertainment, and is powered by an Amlogic premium AI chip. With Nex Playground, cutting-edge AI and computer vision technologies are used to merge digital and physical worlds, immersing players in the experience using their natural body movement. Games range from original sports and fitness titles, to educational games and titles in collaboration with Hasbro, Sesame Workshop, Fruit Ninja and more. Since its founding, Nex has been recognized as one of Fast Company's Most Innovative Companies, TIME's Best Inventions, Parents' Best Entertainment System for Families, and has received RedDot, IDEA, and Core77 international design awards. Nex Playground is also kidSAFE+ COPPA certified, highlighting the company's firm stance on privacy and safety for kids and families.
To learn more, visit https://www.nex.inc or follow the company on Instagram and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604560060/en/
Contacts
BerlinRosen for Nexnex@berlinrosen.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Hypebeast

2 hours ago

• Hypebeast

Supreme x Zoo York 2025 春季最新聯名系列發佈

Supreme本季接著帶來與 Zoo York 的全新聯名系列，Zoo York 是在 1993 年成立於紐約的滑板公司，在當時南加州作為滑板產業和文化中心的背景下，Zoo York 的橫空出世讓世人看見了紐約獨特的滑板風格。 在 1980 年代末和 90 年代初，大多數滑板公司都來自西海岸，並從南加州新興的龐克搖滾中汲取靈感。然而，東海岸的滑板愛好者則與塗鴉和嘻哈等紐約市本土次文化有著更多交集。 Zoo York 在其滑板影片《The Zoo York Mixtape》中清楚捕捉了彼此的連結。 《Zoo York Mixtape》由 RB Umali 拍攝，於 1997 年在紐約地下電影節首映，收錄了 Harold Hunter、Jefferson Pang、Robbie Gangemi 和 Peter Bici 等團隊成員的滑板片段，以及 Method Man、Ghost Killah、Busta Rhymes 和 Fat Joe 在 Stretch and Bobbitoface 電台節目中的自由式滑板片段，能看到滑板愛好者們是如何以他們獨特的勇氣和風格來應對紐約嚴酷的氣候和崎嶇街道。 《Zoo York Mixtape》對滑板運動在隨後十年全球的發展產生了革命性的影響。如今，這部 MV 已成為紐約滑板和嘻哈史上黃金時代的見證。 Supreme 與 Zoo York 合作的 2025 年春季系列包含足球衫、連帽衛衣、寬鬆牛仔褲、足球短褲、T-Shirt、棒球帽、毛帽、滑板和 Spitfire® 輪子等品相，並提供不同配色可選，預計在 6 月 19 日正式發售，亞洲地區為 6 月 21 日，有興趣的讀者不妨多加留意。

Business Wire

8 hours ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.

CBS News

a day ago

• CBS News

Colorado woman transforms old fortune cookie factory into art gallery

Tucked away in a central Denver neighborhood is a building with a story to tell, an old 1940s fortune cookie factory turned art gallery. "I come down here a lot and just sort of contemplate life and the world," said Cookie Factory founder, Amanda Precourt, of an exhibit that's tapped into more than 600 public cameras all over the world that always show a sunrise and a sunset. CBS At the time, the cameras showed a sunrise in Bali, Indonesia, and a sunset in Philipsburg, St. Maarten. It's no surprise the room is one of Precourt's favorite spots in the building she purchased and fell in love with nearly a decade ago. "There were two inches of water and fortune cookies, like the fortunes floating everywhere, and vats that were made for making cookies still in here at the time," said Precourt. "I knew that it would really be amenable and really a positive place to have art of some kind, and came to the space the Cookie Factory is by a series of good fortune." Eight years in the making, the Cookie Factory opened to the public, free of charge, in May. For Amanda, the mission behind the privately funded space is personal. CBS "I hope that the Cookie Factory will allow others to heal through art, as I have in my life. Art has been a very important space and place for me to find mental wellness," said Precourt. "People can use this as a place to gather and connect with friends and be with art, and also to come in total silence and just sit and be with the art, if that is what they need." Its inaugural exhibition features work by artist Sam Falls, created in Colorado's Yampa River Valley. "There's a great quote about art, that art is meant to comfort the afflicted and afflict the comfortable," said Jason Jensdotter, who co-founded Cookie Factory. "I don't know if I agree with it all the way, but food for thought. I think this is a show that definitely comforts. It's based in nature. It is very poetic. There's a lot of poetry to these pieces." CBS The "Nothing without nature" exhibit will run through September, then switch to a new artist. As far as a long-term vision, Precourt is dedicated to keeping it a place for the community. "I really want Cookie Factory to be received and seen as a gift that I'm making to the city," said Precourt. "I just hope that we add more discussion and more space and more places for people to get together and talk about important subjects that art sometimes can elicit."